Baidu
map

Can J Cardiol:房颤患者风险分层及卒中预防治疗

2016-01-26 phylis 译 MedSci原创

背景:加拿大房颤(AF)指南建议对所有房颤患者进行风险分层:卒中,出血和应该接受抗凝治疗。方法:作为加拿大FREEDOM AF 研究的一部分,从474初保健医生处收集了年龄超过18岁以上的患者4670名,这些患者无瓣膜性心脏病(2011年2月到9月)。结果:医生未对15%卒中和25%的出血风险的患者进行评估。当提供预测风险时,仅预测50%卒中和26%出血风险的患者。对大部分人群,过度评估及过低评估

背景:加拿大房颤(AF)指南建议对所有房颤患者进行风险分层:卒中、出血和应该接受抗凝治疗。

方法:作为加拿大FREEDOM AF 研究的一部分,从474名初级保健医生处收集了年龄超过18岁以上的患者4670名,这些患者无瓣膜性心脏病(2011年2月到9月)。

结果:医生未对15%卒中和25%的出血风险的患者进行评估。当提供预测风险时,仅预测50%卒中和26%出血风险的患者。对大部分人群,过度评估及过低评估进行卒中和出血风险的。抗栓治疗包括华法林(90%)治疗;24%的患者(TTR)<50%,9%的患者TTR在50%和60%之间,11%的患者TTR在60%和70%之间,56%的患者TTR≥70%。

结论:在加拿大房颤人群中,初级保健医生不能提供房颤患者的卒中或出血风险。当进行评估时,卒中和出血预测风险指标低于半数的患者。此外,对很大比例的患者过高或过低的估计了卒中和出血风险。约1/3接受华法林的患者TTR小于60%。这些发现为初级护理医生提供了更多的机会增加知识。

原文出处:

Angaran P, Dorian P, et al. The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. Can J Cardiol. 2015 Oct 9.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781696, encodeId=34c21e816960c, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 09 05:40:00 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360953, encodeId=02d413609538a, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447387, encodeId=2d32144e38746, content=<a href='/topic/show?id=35cc36081e2' target=_blank style='color:#2F92EE;'>#卒中预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36081, encryptionId=35cc36081e2, topicName=卒中预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd925339785, createdName=陈吴1236, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614292, encodeId=03e81614292e9, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781696, encodeId=34c21e816960c, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 09 05:40:00 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360953, encodeId=02d413609538a, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447387, encodeId=2d32144e38746, content=<a href='/topic/show?id=35cc36081e2' target=_blank style='color:#2F92EE;'>#卒中预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36081, encryptionId=35cc36081e2, topicName=卒中预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd925339785, createdName=陈吴1236, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614292, encodeId=03e81614292e9, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781696, encodeId=34c21e816960c, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 09 05:40:00 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360953, encodeId=02d413609538a, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447387, encodeId=2d32144e38746, content=<a href='/topic/show?id=35cc36081e2' target=_blank style='color:#2F92EE;'>#卒中预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36081, encryptionId=35cc36081e2, topicName=卒中预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd925339785, createdName=陈吴1236, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614292, encodeId=03e81614292e9, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781696, encodeId=34c21e816960c, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Nov 09 05:40:00 CST 2016, time=2016-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360953, encodeId=02d413609538a, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447387, encodeId=2d32144e38746, content=<a href='/topic/show?id=35cc36081e2' target=_blank style='color:#2F92EE;'>#卒中预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36081, encryptionId=35cc36081e2, topicName=卒中预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd925339785, createdName=陈吴1236, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614292, encodeId=03e81614292e9, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Thu Jan 28 12:40:00 CST 2016, time=2016-01-28, status=1, ipAttribution=)]

相关资讯

Stroke:原先存在的心脏疾病是卒中后新诊断房颤发生的主要原因

卒中后新诊断的房颤(nAF)是否反映了潜在的心脏疾病风险,并代表了心源性卒中的风险增加,或者它是否是由神经机制触发的仍然是不确定的。研究人员调查了nAF患者中心血管危险因素和超声心动图参数是否类似于已知AF患者(kAF),并且是否与无AF的患者有所不同。连续的急性缺血性卒中患者被纳入一项前瞻性卒中数据库中。所有患者的超声心动图包括单变量和多变量测试用于比较nAF,kAF和无AF患者的的临床特点及超

Neurology:隐源性卒中后发生房颤的预测指标有哪些?

该研究的目的是评估在隐源性卒中(CS)或短暂性脑缺血发作(TIA)并接受插入心电监护仪(ICM)治疗的患者中房颤(AF)的预测因子。在CRYSTAL AF研究中,研究人员探讨了CS/TIA并随机分配接受ICM的患者的情况。研究人员评估是否年龄,性别,种族,体重指数,类型和指数缺血性事件,CHADS2评分,PR间期,以及糖尿病,高血压,充血性心脏衰竭,或卵圆孔未闭和房性早搏的存在是否能在最初的12和

Chest:治疗脓毒症期间房颤——β受体阻滞剂优于CCBs

脓毒症期间发生房颤(AF)增加发病率和死亡率,但在脓毒症期间有针对性的治疗AF心率和节律的实践模式和结果目前还不清楚。该项回顾性队列研究的数据来自于约20%的美国医院。研究人员确定了脓毒症期间IV级AF治疗的相关因素(β受体阻滞剂[BBs],钙通道阻滞剂[CCBs],地高辛,或胺碘酮)。研究人员使用倾向得分匹配和工具变量的方法来比较不同治疗房颤方法之间的死亡率。在39693例脓毒症期间发生房颤的患

BMJ:房颤是否是女性心血管疾病和死亡的较强风险因素?

该研究的目的是确定女性与男性相比,房颤是否是心血管疾病和死亡的较强的风险因素。原始出处:Connor A Emdin,Christopher X Wong,Allan J Hsiao,et al.Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men,BMJ

J Thorac Cardiovasc Surg:房颤患者手术治疗的预后,男女有别吗?

背景:房颤患者(AF),药物治疗的预后存在性别差异。这篇研究评估,房颤患者进行手术治疗,预后是否存在性别差异。方法:2004年4月到2012年12月,共有936名房颤患者进行手术治疗。采用倾向评分匹配方法按照性别进行预后分析。结果:936例患者中,,571(61%)为男性;女性年龄较大(68.6±11.3岁vs 66.9±11.9岁),心衰发生较多(44% vs 37%;P = 024),二尖瓣手

Circ J:女性是房颤相关的心源性卒中的危险因素

目的:CHA2DS2-VASc评分的大小不仅与中风的发病率有关而且与长期预后相关。AF-相关心源性卒中患者性别和初始卒中严重程度相关性尚未研究。本研究旨在探讨多中心注册研究中,心源性卒中患者初始卒中严重程度的危险因素。方法和结果  :在2001年1月到2013年7月间,研究者从日本标准脑卒中登记中心选择了12701例房颤相关的心源性卒中患者(年龄77±10岁;女性为5653)。应用多变量线性回归确

Baidu
map
Baidu
map
Baidu
map